RxDoctor Payments Data

Katay Bouttamy, DO

Family Medicine · Kings Mountain, NCNPI 1558315721

Payments from drug & device makers

$13,620in general payments, 2019–2025

Across 826 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Pfizer$973
  • Bayer$687
  • Johnson & Johnson$660
  • plus $6K from 43 others

What the payments were for

  • Food & beverage$13,49199%
  • Education$1291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,620 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$92,007
Medicare patients
180
Services billed
1,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide151$168,812
TrulicityDulaglutide71$70,921
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$56,899
EliquisApixaban71$52,331
FarxigaDapagliflozin Propanediol49$35,796
JardianceEmpagliflozin24$28,962
XareltoRivaroxaban47$28,945
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog42$20,383
MounjaroTirzepatide16$19,137
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$13,633
Tresiba Flextouch U-200Insulin Degludec15$10,749
Tresiba Flextouch U-100Insulin Degludec18$8,994
RestasisCyclosporine24$8,055
EntrestoSacubitril/Valsartan11$7,697
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Levemir$1,559$170,185166 claims
Lilly USA, LLCTrulicity, Mounjaro$611$90,05887 claims
GSKTrelegy Ellipta$587$56,89958 claims
PfizerEliquis$973$52,33171 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,586$43,48761 claims
Boehringer IngelheimJardiance$148$28,96224 claims
Johnson & JohnsonXarelto$660$28,94547 claims
AbbVieRestasis$2,031$8,05524 claims
Astellas Pharma US IncMyrbetriq$400$5,20112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Kings Mountain

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →